Freedom Capital Markets Upgrades Alnylam Pharmaceuticals to Buy, Lowers Price Target to $410

Alnylam Pharmaceuticals, Inc -1.20%

Alnylam Pharmaceuticals, Inc

ALNY

313.41

-1.20%

Freedom Capital Markets analyst Ilya Zubkov upgrades Alnylam Pharmaceuticals (NASDAQ: ALNY) from Hold to Buy and lowers the price target from $470 to $410.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via